RxDoctor Payments Data

Jaime Burns, APRN

Family · Clearwater, FLNPI 1679069959

Payments from drug & device makers

$19,120in general payments, 2019–2025

Across 1,103 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$1K
  • Pfizer$969
  • Eisai Inc.$940
  • Jazz Pharmaceuticals Inc.$842
  • Teva Pharmaceuticals USA, Inc.$830
  • plus $11K from 54 others

What the payments were for

  • Travel & lodging$100%
  • Food & beverage$18,96699%
  • Education$1441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)160$2,622
UCB, Inc.83$1,389
Pfizer66$969
Eisai Inc.53$940
Jazz Pharmaceuticals Inc.32$842
Teva Pharmaceuticals USA, Inc.71$830
Novartis50$792
Neurocrine Biosciences, Inc.52$786
Amgen(2 entities)35$717
SK Life Science, Inc.30$685
Lundbeck LLC29$608
Lilly USA, LLC31$588
Impel Pharmaceuticals Inc.34$517
Biohaven Pharmaceutical Holding Company Ltd.24$466
Otsuka America Pharmaceutical, Inc.35$454
Axsome Therapeutics, Inc.21$381
Amneal Pharmaceuticals LLC21$341
Acadia Pharmaceuticals Inc14$335
Argenx US, Inc.13$301
AstraZeneca12$280
Bristol Myers Squibb10$279
MDD US Operations, LLC22$253
Acorda Therapeutics, Inc13$250
CSL Behring11$238
Scilex Pharmaceuticals Inc.11$212
Sunovion Pharmaceuticals Inc.11$201
Sumitomo Pharma America, Inc.16$190
Impel Pharmaceuticals LLC13$188
Octapharma USA, Inc.5$185
Neurelis, Inc.8$170
Harmony Biosciences LLC6$159
TG Therapeutics, Inc.6$149
Vanda Pharmaceuticals Inc.8$143
Biogen8$138
Catalyst Pharmaceuticals, Inc.7$137
Azurity Pharmaceuticals, Inc.7$129
Biohaven Pharmaceuticals, Inc.12$126
Adamas Pharmaceuticals, Inc.7$121
Mallinckrodt Hospital Products Inc.5$110
EMD Serono, Inc.4$82
Collegium Pharmaceutical, Inc.5$80
Upsher-smith Laboratories LLC4$69
Johnson & Johnson(2 entities)5$67
Merz Pharmaceuticals, LLC3$67
Avanir Pharmaceuticals, Inc.4$66
Kyowa Kirin, Inc.3$49
Tanabe Pharma America, Inc.2$48
Genentech USA, Inc.3$47
Abbott1$32
Arbor Pharmaceuticals, Inc.2$28
Supernus Pharmaceuticals, Inc.2$28
Medtronic1$27
Greenwich Biosciences, Inc.2$26
Banner Life Sciences, LLC2$26
Si-bone, Inc.1$22
Avion Pharmaceuticals1$21
Merck1$20
Grifols USA, LLC1$20
C2n Diagnostics, LLC1$20
Nevro Corp.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,120 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$15,243
Medicare patients
94
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab30$320,086
IngrezzaValbenazine Tosylate36$299,521
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5011$197,073
Nurtec OdtRimegepant Sulfate95$163,986
UbrelvyUbrogepant82$133,155
AptiomEslicarbazepine Acetate55$101,065
AustedoDeutetrabenazine16$96,342
NuplazidPimavanserin Tartrate19$95,586
QuliptaAtogepant52$80,667
Aimovig AutoinjectorErenumab-Aooe58$78,222
GocovriAmantadine Hcl47$77,604
BotoxOnabotulinumtoxina50$60,296
EpidiolexCannabidiol (Cbd)14$58,909
Emgality SyringeGalcanezumab-Gnlm34$53,019
RytaryCarbidopa/Levodopa45$38,760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$786$299,52136 claims
AbbVieUbrelvy, Qulipta, Botox$2,622$274,117184 claims
CSL BehringPrivigen$238$197,07311 claims
PfizerNurtec Odt$969$163,98695 claims
Sunovion Pharmaceuticals Inc.Aptiom$201$101,06555 claims
Teva Pharmaceuticals USA, Inc.Austedo$830$96,34216 claims
Acadia Pharmaceuticals IncNuplazid$335$95,58619 claims
MDD US Operations, LLCGocovri$253$77,60447 claims
Eisai Inc.Fycompa, Dayvigo$940$40,72546 claims
Amneal Pharmaceuticals LLCRytary$341$38,76045 claims
Kyowa Kirin, Inc.Nourianz$49$30,25716 claims
UCB, Inc.Briviact$1,389$25,26617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →